Yogev Shamay

RevitalVision is a SaaS-based, digital health startup offering a unique solution to 500 million people whose needs are unmet by existing vision treatments. Our non-invasive technology enhances eyesight neurologically. Its thousands of clinical trial participants and commercial customers have reported and tested with significant improvement in their vision performance by 2.5 lines on the visual acuity eye chart, and a 100% increase in contrast sensitivity on average for all product categories. We offer eye care specialists a simple, easy-to-use tool to improve patient's vision beyond current eye treatments, and an additional revenue channel. We also offer eye surgery clinics a unique tool to reduce non-paid post-surgery visits of cataract and refractive patients. RevitalVision is the only FDA-cleared product for children older than 9 and adults with amblyopia a leading cause for impaired vision affecting 3-5% of the world population. Brain science and proprietary algorithm-based technology, clinically validated in multiple eye diseases and vision impairments, and has been approved for two new USA CPT codes by the American Medical Association for the treatment of amblyopia. RevitalVision is also CE-Marked with a broad indication for use, for vision improvement above age 9.